Evidence map›Paper›PMID 37553212›Full record

ArticleCold Spring Harbor perspectives in medicine2023

Cancer Metabolism Historical Perspectives: A Chronicle of Controversies and Consensus.

Chi V Dang

Open access · bronzeAbstract read
In one paragraph

Article in Cold Spring Harbor perspectives in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. OPPORTUNITIES AND CHALLENGES FOR TARGETING CANCER METABOLISM.Transactions of the American Clinical and Climatological Association · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Chi V DangLudwig Institute for Cancer Research, New York, New York 10017, USA cvdang@jhmi.edu cdang@lcr.org.
Johns Hopkins Medicine · US

Funding

C-MYC TARGETS IN THE PATHOGENESIS OF HUMAN CANCERSR01CA057341 · NCI · WISTAR INSTITUTE · PI DANG, CHI V. · 1992 to 2021
$8.3M
MYC--TRANSCRIPTION AND INTERACTION WITH P107R01CA051497 · NCI · WISTAR INSTITUTE · PI DANG, CHI V. · 1995 to 2025
$5.3M
C MYC--TRANSCRIPTION AND APOPTOSISR37CA051497 · NCI · JOHNS HOPKINS UNIVERSITY · PI DANG, CHI V. · 1999 to 2006
$2.8M
Defining metabolic adaptations within the PDAC "arid" tumor microenvironmentR01CA252225 · NCI · WISTAR INSTITUTE · PI DANG, CHI V., STANGER, BEN Z · 2021 to 2025
$2.8M
NCI NIH HHS R01 CA051497NCI NIH HHS R01 CA057341NCI NIH HHS R01 CA252225NCI NIH HHS R37 CA051497
6 · The paper itself

Abstract

A century ago, Otto Warburg's work sparked the field of cancer metabolism, which has since taken a tortuous path. As evidence accumulated over the decades, consensus views of causes of cancer emerged, whereby genetic and epigenetic oncogenic drivers promoted immune evasion and induced new blood vessels and neoplastic metabolism to support tumor growth. Neoplastic cells abandon social cues of intercellular cooperation, escape tissue confinement, metastasize, and ultimately kill the host. Herein, key milestones in the study of cancer metabolism are chronicled with an emphasis on carbohydrate metabolism. The field began with a cancer cell-autonomous view that has been refined by a richer understanding of solid cancers as growing, immune-suppressive, complex organs comprising different cell types that are nourished by a variety of nutrients and variable amounts of oxygen through abnormal neovasculatures. Based on foundational historical studies, our current understanding of cancer metabolism offers a hopeful outlook for targeting metabolism to enhance cancer therapy.

Identifiers

PMID37553212
PMCPMC10691493
OpenAlexW4385667613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.